聚乙二醇水凝胶在宫颈癌根治性同步放化疗中的剂量学与临床效果:3期前瞻性多中心随机对照试验
这项在中国9个中心开展的3期随机对照试验纳入94例宫颈癌根治性同步放化疗患者,比较外照射后注射10 mL聚乙二醇水凝胶与不注射的效果。水凝胶组直肠D2cc、D0.1cc和D5cc剂量均显著降低,其他器官剂量无显著变化,急慢性放射性直肠损伤和QOL无显著差异,但水凝胶组便秘和症状体验评分更高,并出现1例直肠阴道瘘。
要点
- 聚乙二醇水凝胶显著降低宫颈癌近距离放疗时直肠D2cc、D0.1cc和D5cc剂量。
- 水凝胶增加宫体-直肠距离并维持至治疗后24周,24-36周明显吸收。
- 急慢性放射性直肠损伤和QOL无显著差异,但水凝胶组便秘和症状体验评分更高。
核心结论
- 聚乙二醇水凝胶注射可有效降低宫颈癌根治性同步放化疗中直肠受照剂量,且不增加其他器官剂量。
- 整体安全性和生活质量得以保持,尽管存在短暂生活质量变化和孤立性直肠阴道瘘。
研究设计与样本
- 3期随机平行对照试验(NCT05690906),在中国9个中心开展,时间2022年7月至2025年1月。
- 94例分析患者按1:1随机分配至10 mL聚乙二醇水凝胶注射组(45例)或无注射对照组(49例)。
- 外照射50.4 Gy/28次或45 Gy/25次后行三维图像引导近距离放疗,处方剂量6 Gy×5次或7 Gy×4次,同步化疗,随访72周。
主要发现
- 水凝胶组直肠D2cc为64.23±6.58 Gy,对照组为69.79±6.10 Gy(P < .001)。
- 水凝胶组直肠D0.1cc为74.67±12.22 Gy,对照组为84.38±9.91 Gy(P < .001)。
- 水凝胶组直肠D5cc为60.23±4.96 Gy,对照组为63.18±5.04 Gy(P = .003)。
- 其他器官剂量无显著变化;水凝胶增加宫体-直肠距离并维持至治疗后24周,24-36周明显吸收。
- 急性放射性直肠损伤发生率水凝胶组55.6% vs 对照组46.9%,慢性损伤9.5% vs 16.7%,QOL评分无显著差异,但水凝胶组便秘和症状体验评分更高;水凝胶组发生1例(2.2%)直肠阴道瘘,无其他≥3级不良事件。
关键数值与推荐
- 主要终点为累积直肠D2cc剂量。
- 次要终点包括直肠D0.1cc和D5cc剂量、乙状结肠/膀胱/小肠D2cc、直肠周围间隙和凝胶体积变化、QOL评分(QLQ-C30和QLQ-CX24)及放射性直肠损伤发生率。
临床怎么用
- 对于宫颈癌根治性同步放化疗患者,可考虑在外照射后注射10 mL聚乙二醇水凝胶以降低直肠受照剂量。
- 需关注水凝胶组便秘和症状体验评分升高以及直肠阴道瘘风险,个体化评估获益与风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study evaluated the safety and efficacy of polyethylene glycol (PEG) hydrogels in reducing rectal radiation dose and complication during cervical cancer radical concurrent chemoradiation therapy. METHODS AND MATERIALS: This phase 3, randomized, parallel-controlled trial (NCT05690906) conducted across 9 centers in China (July 2022-January 2025). Participants were randomly assigned 1:1 to receive a 10 mL PEG hydrogel injection (experimental group) or no injection (control group) after 50.4 Gy/28 fractions (f) or 45 Gy/25 f external beam radiation therapy. Three-dimensional image guided brachytherapy plans were developed before each brachytherapy session using computed tomography or magnetic resonance imaging (MRI) imaging, delivered in a prescribed dose of 6 Gy × 5 f or 7 Gy × 4 f. Concurrent chemotherapy was administered during the radiation therapy course. Patients were followed up for 72 weeks. The primary endpoint was the cumulative rectal D2cc dose. Secondary endpoints included rectal D0.1cc and D5cc doses and D2cc of the sigmoid, bladder, and small intestine; changes in the perirectal space and hydrogel volume; quality of life (QOL) scores (QLQ-C30 and QLQ-CX24); and incidence of radiation-induced rectal complication. QOL was assessed before brachytherapy, immediately after completing brachytherapy, and at 4, 12, 24, 36, 48, and 72 weeks after brachytherapy. Radiation-induced rectal complication was assessed at each of the aforementioned follow-up timepoints and additionally evaluated on a weekly basis throughout the entire radiation therapy course. RESULTS: Of 94 analyzed patients (45 experimental and 49 control), the experimental group showed significant reductions in rectal D2cc (64.23 ± 6.58 Gy vs 69.79 ± 6.10 Gy; P < .001), D0.1cc (74.67 ± 12.22 Gy vs 84.38 ± 9.91 Gy; P < .001), and D5cc (60.23 ± 4.96 Gy vs 63.18 ± 5.04 Gy; P = .003) doses, with no significant changes in doses to other organs The hydrogel increased the cervix-rectum distance during brachytherapy and remained stable until 24 weeks after treatment, with noticeable absorption occurring between weeks 24 and 36. No significant differences were observed between experimental group and control group in acute radiation-induced rectal injuries (55.6% vs 46.9%), chronic injuries (9.5% vs 16.7%), or QOL scores, except for higher constipation scores and symptom experience scores in the experimental group. One case (2.2%) of rectovaginal fistula occurred in the experimental group, with no other grade ≥3 adverse events observed. CONCLUSIONS: PEG hydrogel injection effectively reduced rectal radiation dose during cervical cancer radical concurrent chemoradiation therapy without increasing doses to other organs, preserving overall safety and QOL despite transient QOL variations and an isolated rectovaginal fistula.
引用
- Wang Y, Zhang X, Wang F, et al. Dosimetric and Clinical Effects of Polyethylene Glycol Gel in Radical Concurrent Chemoradiation Therapy for Cervical Cancer: A Phase 3 Prospective Multicenter Randomized Controlled Trial. Int J Radiat Oncol Biol Phys. 2025. PMID: 40876576. doi:10.1016/j.ijrobp.2025.08.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。